Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.

Journal of pharmacokinetics and pharmacodynamics - 1 Dec 2014

Conrado Daniela J, Denney William S, Chen Danny, Ito Kaori

Abstract excerpt

Our objective was to expand our understanding of the predictors of Alzheimer's disease (AD) progression to help design a clinical trial on a novel AD medication. We utilized the Coalition Against Major Diseases AD dataset consisting of control-arm data (both placebo and stable background AD medication) from 15 randomized double-blind clinical trials in mild-to-moderate AD patients (4,495 patients; July 2013). Our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Apolipoprotein E4

Share to Clinical Trials as Topic

Share to Disease Progression

Share to Double-Blind Method

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 25168488
DOI: 10.1007/s10928-014-9375-z

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.PMID 25168488Read ↗

An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.Semantic proximity Read ↗

Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's DiseaseSemantic proximity Read ↗

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read ↗

Identifying underlying patterns in Alzheimer's disease trajectory: a deep learning approach and Mendelian randomization analysisSemantic proximity Read ↗

A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical TrialsSemantic proximity Read ↗

Combination therapies delay cognitive decline over 10 years in Alzheimer’s NACC participantsSemantic proximity Read ↗

Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer’s disease using ADNISemantic proximity Read ↗

Development of a prediction model of conversion to Alzheimer’s disease in subjects with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR projectSemantic proximity Read ↗

Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept TrialSemantic proximity Read ↗

Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.Semantic proximity Read ↗

Multi-method investigation of factors influencing amyloid onset and impairment in three cohortsSemantic proximity Read ↗

Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.